Pimavanserin Tartrate

酒石酸匹莫范色林

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NamePimavanserin Tartrate
Drug Alias Name酒石酸匹玛色林pimavanserinapimavanserinum酒石酸哌马色林匹莫范色林 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor inverse agonists
TargetsSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsSchizophreniaPsychotic DisordersAutism Spectrum Disorder +[11] 
Global Approved IndicationsHallucinations
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/04/29
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAcadia Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesHumanis Saglık Anonim SirketiThe Ohio State UniversityAcadia Pharmaceuticals Inc +[9] 
Inactive CompaniesState University Of New York - Downstate Medical CenterNational Institute Of Neurological Disorders And StrokeTianjin Tasly Sants Pharmaceutical Co Ltd
Active IndicationsSchizophreniaAutism Spectrum DisorderDisruptive, Impulse Control, and Conduct Disorders +[7] 
Inactive IndicationsPsychotic DisordersDepressive Disorder, MajorDyskinesias +[4] 

Other Information

ATC CodeN05AX17
Related LinksWikipediaDrugBankKEGG